Functional dyspepsia

Last updated
Functional dyspepsia
Other namesNon-ulcer dyspepsia
Symptoms-stomach-pain.jpg
Stomach pain is a common symptom of functional dyspepsia.
Symptoms Early satiety, heartburn, nausea, postprandial fullness, vomiting, and/or epigastric pain. [1]
Complications Symptoms of anxiety, depression, and somatization. [2]
TypesPostprandial distress syndrome and epigastric pain syndrome. [1]
Diagnostic method Rome IV criteria. [1]
Differential diagnosis Gastroesophageal reflux disease, gastroparesis, and irritable bowel syndrome. [1]
TreatmentSymptom control. [2]
Medication Proton pump inhibitors, H2 receptor antagonists, antidepressants, and prokinetic agents. [2]
Prognosis 15% to 20% of patients have persistent symptoms during extended follow-up. [2]
Frequency5-11% worldwide. [1]

Functional dyspepsia (FD) is a common gastrointestinal disorder defined by symptoms arising from the gastroduodenal region in the absence of an underlying organic disease that could easily explain the symptoms. [3] Characteristic symptoms include epigastric burning, epigastric pain, postprandial fullness, and early satiety. FD was formerly known as non-ulcer dyspepsia, as opposed to "organic dyspepsia" with underlying conditions of gastritis, peptic ulcer disease, or cancer.

Contents

The exact cause of functional dyspepsia is unknown however there has been many hypotheses regarding the mechanisms. Theories behind the pathophysiology of functional dyspepsia include gastroduodenal motility, gastroduodenal sensitivity, intestinal microbiota, immune dysfunction, gut-brain axis dysfunction, abnormalities of gastric electrical rhythm, and autonomic nervous system/central nervous system dysregulation. Risk factors for developing functional dyspepsia include female sex, smoking, non-steroidal anti-inflammatory medication use, and H pylori infection. Gastrointestinal infections can trigger the onset of functional dyspepsia.

Functional dyspepsia is diagnosed based on clinical criteria and symptoms. Depending on the symptoms present people suspected of having FD may need blood work, imaging, or endoscopies to confirm the diagnosis of functional dyspepsia. Functional dyspepsia is further classified into two subtypes, postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS).

Functional dyspepsia can be managed with medications such as prokinetic agents, fundus-relaxing drugs, centrally acting neuromodulators, and proton pump inhibitors. Up to 15-20% of patients with functional dyspepsia experience persistent symptoms. Functional dyspepsia is more common in women than men. In Western nations, the prevalence is believed to be 10-40% and 5-30% in Asian nations.

Signs and symptoms

Symptoms of functional dyspepsia include epigastric burning, epigastric pain, postprandial fullness (often described as bloating by those who have FD), and early satiety. [4] Food consumption frequently makes symptoms worse. [5] Although functional dyspepsia is typically chronic, the symptoms are generally sporadic, even during periods of severe symptoms. [6]

Those with FD typically refer to early satiety as a vague abundance of gas after eating or discomfort, but in reality, what they truly mean is that they find it difficult to finish a normal-sized meal because they are uncomfortable or feel full. [4]

While nausea and heartburn are still possible co-occurring symptoms, they are no longer regarded as major dyspeptic symptoms and may originate from different processes. When certain symptoms occur, such as vomiting, a coexisting or alternative condition, like gastroparesis, needs to be evaluated. [4]

Causes

Functional dyspepsia has a wide range of complex etiologies. [7] Gastric motor function abnormalities have long been linked to functional dyspepsia. [8] [9] However, a study revealed that there was no relationship between symptoms and stomach physiological abnormalities. [10] The symptoms are significantly influenced by meal consumption, [11] and genetic factors may also play a part. [12]

Risk factors

Several epidemiological studies have demonstrated a moderate correlation between dyspepsia in the general population and female sex, smoking, non-steroidal anti-inflammatory medication use, and H pylori infection. [13] In one long-term investigation, a high body mass index was an independent predictor of the emergence of functional dyspepsia. [14]

Since the brain and gut communicate through the hypothalamic-pituitary-adrenal axis and the enteric nerve system, psychological comorbidity plays a significant influence in the development of functional dyspepsia. [15] Anxious participants had an eight-fold increased risk of developing functional dyspepsia compared to those without anxiety in a population-based survey conducted in Sweden. [16] According to two Australian longitudinal investigations, there are reciprocal effects between the stomach and the brain. Specifically, people who had functional dyspepsia at baseline were more likely than those who did not experience anxiety or depression during follow-up. [17] [18]

Triggers

Acute gastroenteritis can lead to the development of post-infection functional dyspepsia. [15] According to a meta-analysis of 19 papers, exposed people had nearly three times the chance of developing functional dyspepsia over the course of more than six months following an infection compared to non-exposed people. [19]

Mechanism

Because functional dyspepsia symptoms are complicated and vary so much, the underlying pathophysiology of the disorder is still unknown. [15] The causes of dyspeptic symptoms have been attributed to a number of pathophysiologic processes. These include gastroduodenal motility, gastroduodenal sensitivity, intestinal microbiota, immune dysfunction, gut-brain axis dysfunction, abnormalities of gastric electrical rhythm, and autonomic nervous system/central nervous system dysregulation. [5] [12] [15]

Gastroduodenal motility

Patients with functional dyspepsia frequently have sensorimotor abnormalities of the gastroduodenum, including altered motility and pathological reactions to mechanical and chemical stimuli. [20]

One of the main pathophysiologic mechanisms thought to underlie the symptoms of functional dyspepsia is delayed stomach emptying. Several studies have looked into the connection between the pattern and intensity of symptoms and delayed stomach emptying. [21] The proportion of dyspeptic individuals with delayed stomach emptying varies from 20% to 50%, depending on the study. [22] [23]

In response to gastric balloon distension during fasting and following meal intake, patients with functional dyspepsia demonstrate impaired proximal stomach accommodation. [24] [25] Due to the poor accommodation, there is a disproportional volume distribution, with the fundus volume being less and the antral volume being bigger than usual. [26] Furthermore, individuals suffering from functional dyspepsia exhibit compromised fundus accommodation in reaction to duodenal distension. [27]

Gastroduodenal sensitivity

In functional dyspepsia, the stomach's sensitivity to chemical and mechanical stimuli is changed. [12]  After fasting and meal consumption, patients with functional dyspepsia exhibit visceral hypersensitivity following gastric fundus distension. [20] [28] Following stomach distension, even patients with normal accommodation experience discomfort. [29] Additionally, some individuals exhibit hypersensitivity to distension of the duodenum, [30] jejunum, [29] or rectal cavity, [31] indicating a more widespread sensitization of the central and autonomic nervous systems. [12]

Intestinal microbiota

The small intestinal microbiota has been identified as a possible contributing factor. [15] In one study, an elevated duodenal mucosal bacterial load was inversely connected with quality of life and correlated with meal-related symptoms during a nutritional challenge test, despite the fact that relative bacterial abundance in the small intestine is difficult to interpret. [32] The bile acid pool may vary as a result of microbiome modifications brought on by small intestine inflammation. [33]

On the other hand, a decrease in primary bile acid levels may have an impact on the small intestine's microbial diversity, which may promote the proliferation of proinflammatory bacteria and low-grade inflammation, both of which may result in the breakdown of the epithelial barrier. [33] [34]

A shift in the ratio of main to secondary bile acids and decreased amounts of total bile acids in certain patients with functional dyspepsia during fasting further suggest the involvement of gastrointestinal microbes. [35]

Immune dysfunction

Some other functional gastrointestinal disorders have been linked to low-grade mucosal inflammation and elevated quantities of inflammatory cells, such as intraepithelial lymphocytes and mast cells. [36]

The quantity of cell-surface markers needed for more proliferation or differentiation of specialized cells, however, does not increase in functional dyspepsia; rather, it indicates the active state of these cells. [37]

Reduced expression of two markers—FAS, which is involved in lymphocyte homoeostasis and cell apoptosis, and HLA-DRA, which is involved in B-cell proliferation—has been linked to functional dyspepsia and is thought to reflect changes in duodenal lymphocyte populations. [38]

Moreover, duodenal eosinophilia has been linked to symptoms of postprandial distress syndrome, as opposed to an increase in mast cells. [39] [40]

Gut-brain axis dysfunction

There is a subpopulation of people with functional dyspepsia who have involvement in the gut-brain axis. Through the hypothalamic-pituitary-adrenal axis, changes in epithelial barrier function brought on by immune system and gastrointestinal microbiota disruptions can control gut-brain connections. [15] The mechanisms involving corticotropin-releasing hormone and stress play a significant part in gastrointestinal permeability. [41] This impact has been demonstrated in controlled trials including healthy volunteers under stress as well as in animal models of functional dyspepsia. [42] [43] Anatomical and functional connectivity impairments were observed in brain regions important for processing visceral afferent information in patients with functional dyspepsia, according to MRI results. [44] [45]

Abnormalities of gastric electrical rhythm

Additionally, there is proof that up to two thirds of patients with functional dyspepsia have anomalies in the underlying stomach myoelectrical activity, as determined by cutaneous electrogastrography. It is yet unknown how this discovery relates to stomach emptying and symptom patterns. There was no association discovered between the pattern of dyspeptic symptoms and the existence of electrogastrography results. There has been good evidence of a relationship between aberrant gastric electrical rhythm and delayed stomach emptying. [46] [47]

Autonomic nervous system/central nervous system dysregulation

It has been proposed that certain patients with functional dyspepsia may have anomalies in their autonomic nervous system. Particularly, it has been suggested that efferent vagal dysfunction [48] may be the cause of antral hypomotility [49] and poor adaption to a meal. [50] Additionally, there is proof that psychological variables and both stomach functionality and symptoms of functional dyspepsia are related to psychopathology. Low vagal activity has been suggested as the mediating mechanism in these relationships. [51] [52]

Diagnosis

Functional dyspepsia is diagnosed using clinical symptoms and Rome IV criteria, which were recently revised. [53] The clinical examination and patient history should look for alarm symptoms. Alarm symptoms include dysphagia, especially if progressive, or odynophagia, overt gastrointestinal bleeding, such as melena or hematemesis, persistent vomiting, unintentional weight loss, family history of gastric or esophageal cancer, palpable abdominal or epigastric mass or abdominal adenopathy, and signs of iron-deficiency anemia. [12]

The diagnostic criteria for functional dyspepsia is as follows: [54]

At least one of the following: [54]

  1. Troublesome postprandial fullness. [54]
  2. Troublesome early satiation. [54]
  3. Troublesome epigastric pain. [54]
  4. Troublesome epigastric burning. [54]

The criteria must be met over the past three months, with the onset of symptoms occurring at least six months before diagnosis and there must be an absence of structural disease evidence that could account for the symptoms, including upper endoscopy. [54]

Taking a thorough history that includes all relevant symptoms is the first step in the process. Patients are then categorized into the relevant subtype and any alarm symptoms or indicators that might point to a different diagnosis are reviewed. [15]

The following step is a thorough physical examination, which is crucial for a number of reasons. Patients are first reassured by the examination that their problems are being addressed seriously. Second, even in a patient with typical symptoms, the examination may yield results that point to a different diagnosis. [15]

Unfortunately, there is currently no reliable biomarker to aid in the diagnosis, and history and clinical examination cannot reliably differentiate functional dyspepsia from organic dyspepsia causes. [55] There is no validated diagnostic algorithm, and current guidelines and the Rome committee oppose routine laboratory testing in all patients. [53] [56] Requesting a complete blood count is probably a good idea because anemia diagnosis could alter the final diagnosis. Liver function tests are needed if there is concern regarding a potential hepatobiliary cause of severe episodic epigastric discomfort. [15] It is not advised to regularly monitor thyroid testing or celiac serology, nor is it advised to frequently screen for pancreatitis using serum lipase or amylase levels. [57]

While a negative endoscopy is strictly necessary to validate a functional dyspepsia diagnosis, [53] the majority of dyspepsia patients (80%) have been reported to have no organic abnormalities at endoscopy, with under 10 percent having a peptic ulcer and fewer than 0,5% having gastro-esophageal cancer. [58] The most recent guidelines for managing dyspepsia prohibit endoscopic use in patients under 60 years of age because its low yield, even in cases where alarm symptoms are present. [56] Noninvasive urea breath tests or stool antigen testing for H pylori should be performed on these patients. [15] People who have chronic symptoms should be considered candidates for endoscopy. Gastric biopsies should also be taken, and if H pylori is found, treatment for the infection should begin. [59] [60]

Because of the low yield, routinely requesting an abdominal ultrasound or CT scan in the absence of alarm symptoms or signs is not advised. [61] Up to 25% of individuals with functional dyspepsia display delayed stomach emptying, making gastric emptying investigations of little benefit despite the significant symptom overlap and diagnostic confusion between gastroparesis and functional dyspepsia. [10]

Differential diagnoses for functional dyspepsia include gastro-oesophageal reflux disease, medication side effects, chronic mesenteric ischemia, symptomatic gallstone disease, sphincter of Oddi dysfunction, biliary dyskinesia, or gallbladder cancer, Crohn's disease, peptic ulcer disease (and infection with Helicobacter pylori), infiltrative diseases such as eosinophilic gastroenteritis, sarcoidosis, and amyloidosis, gastro-oesophageal malignancy, gastrointestinal complications of parasites such as giardia lamblia, strongyloides, and anisakiasis, gastroparesis, chronic pancreatitis or pancreatic cancer, and hepatocellular carcinoma. [15]

Classification

The Rome IV criteria further classifies functional dyspepsia into two subtypes, postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). [54] Postprandial distress syndrome is marked by dyspeptic symptoms brought on by meals, such as postprandial fullness and early satiety and accounts for 69% of patients with functional dyspepsia. Epigastric pain syndrome is characterized by burning or pain in the stomach that may not always happen after eating and accounts for 7% of patients. 25% of patients have overlapping PDS and EPS. [62]

Treatment

Treatment for functional dyspepsia involves addressing the predominant symptom or symptoms with a realistic discussion of the limitations of available therapies to manage expectations, as well as providing reassurance that there is no structural cause for the symptoms and an explanation of the pathophysiology and natural history of the disorder. [15]

For individuals with functional dyspepsia who are infected, H. pylori eradication treatment is recommended in all guidelines because it can potentially alleviate symptoms and reduce the risk of developing stomach cancer and peptic ulcers. [63] [64]

Although they haven't been thoroughly investigated, dietary and lifestyle changes are typically advised. It makes sense to advise patients to eat smaller, more frequent meals and to steer clear of foods that worsen their symptoms. [5] Eating less fattening meals may be advised because the duodenum's lipid content increases the stomach's mechanosensitivity. [65] [66] Although there is no proof connecting coffee and spicy meals high in capsaicin to symptoms, they are generally avoided. [67] [68]

Prokinetic medications are effective in treating functional dyspepsia by stimulating the contractions of the stomach's smooth muscle and have been suggested as initial treatments for PDS. Prokinetics include agonists of the 5-HT receptor 4 (5-HT4), antagonists of the D(2) dopamine receptor, and agonists of the motilin receptor, such erythromycin. There aren't many high-quality trials and there's frequently little evidence in the literature supporting their symptomatic benefit. [69]

5-HT1A agonists, muscarinic auto-receptor antagonists, and acetylcholinesterase inhibitors, such as acotiamide, can all target impaired stomach accommodation. [69] Research has demonstrated that the 5-HT1A agonists buspirone, [70] tandospirone, [71] and acotiamide are beneficial for PDS symptoms. [72]

Numerous, frequently tiny,??? investigations have assessed centrally acting neuromodulators in the context of functional dyspepsia. Its reasoning stems from the common occurrence of psychiatric comorbidity and the theory that visceral hypersensitivity may react to centrally active neuromodulators and play a role in the development of symptoms. These medications are most likely the most helpful for EPS. However, similar to 5-HT1A agonists that act on stomach accommodation, they may also have therapeutic effects in PDS through their effects on gastrointestinal motility. [12] When administered at a modest dosage in the evening, the antidepressant mirtazapine has demonstrated effectiveness in treating early satiety and nausea in individuals with functional dyspepsia who have lost weight and do not exhibit clinically significant co-occurring depression or anxiety. [73]

The most widely utilized first-line therapy for functional dyspepsia is inhibition of acid secretion. [12] The results indicate that gastro-esophageal reflux disease is the principal indication, as response rates are highest (up to 45%) in patients with associated heartburn. [74] Compared to people with PDS, those with EPS are more likely to respond. [75]

Outlook

The natural history of most people with functional dyspepsia is chronic and variable, consisting of periods during which the patient has no symptoms at all interspersed with phases of symptom return. [76]

According to data from population-based studies, during an extended period of follow-up, 15–20% of patients with functional dyspepsia may experience persistent symptoms, and 50–35% may experience a resolution of symptoms; the remaining 30–35% of patients may experience fluctuating symptoms that meet the criteria for another functional gastrointestinal disorder. [77]

Functional dyspepsia is a chronic condition, although there is no proof that it is linked to a lower chance of survival. [78]

Epidemiology

Regardless of the various functional dyspepsia criteria, the population prevalence of the disorder varies greatly around the world, with high overall rates (10–40%) in Western nations and low overall rates (5–30%) in Asian nations. [79] Women are more likely than males to experience functional dyspepsia. [80]

See also

Related Research Articles

<span class="mw-page-title-main">Proton-pump inhibitor</span> Class of drugs for reducing stomach acid

Proton-pump inhibitors (PPIs) are a class of medications that cause a profound and prolonged reduction of stomach acid production. They do so by irreversibly inhibiting the stomach's H+/K+ ATPase proton pump.

<span class="mw-page-title-main">Duodenum</span> First section of the small intestine

The duodenum is the first section of the small intestine in most higher vertebrates, including mammals, reptiles, and birds. In mammals, it may be the principal site for iron absorption. The duodenum precedes the jejunum and ileum and is the shortest part of the small intestine.

Heartburn, also known as pyrosis, cardialgia or acid indigestion, is a burning sensation in the central chest or upper central abdomen. Heartburn is usually due to regurgitation of gastric acid into the esophagus. It is the major symptom of gastroesophageal reflux disease (GERD).

Functional abdominal pain syndrome (FAPS), chronic functional abdominal pain (CFAP), or centrally mediated abdominal pain syndrome (CMAP) is a pain syndrome of the abdomen, that has been present for at least six months, is not well connected to gastrointestinal function, and is accompanied by some loss of everyday activities. The discomfort is persistent, near-constant, or regularly reoccurring. The absence of symptom association with food intake or defecation distinguishes functional abdominal pain syndrome from other functional gastrointestinal illnesses, such as irritable bowel syndrome (IBS) and functional dyspepsia.

<span class="mw-page-title-main">Gastroptosis</span> Downward displacement of the stomach

Gastroptosis is the abnormal downward dislocation (ptosis) of the stomach in which its greater curve is displaced below the iliac crest. It is a life-threatening condition.

Functional gastrointestinal disorders (FGID), also known as disorders of gut–brain interaction, include a number of separate idiopathic disorders which affect different parts of the gastrointestinal tract and involve visceral hypersensitivity and motility disturbances.

Indigestion, also known as dyspepsia or upset stomach, is a condition of impaired digestion. Symptoms may include upper abdominal fullness, heartburn, nausea, belching, or upper abdominal pain. People may also experience feeling full earlier than expected when eating. Indigestion is relatively common, affecting 20% of people at some point during their life, and is frequently caused by gastroesophageal reflux disease (GERD) or gastritis.

A gastrointestinal cocktail,, is a mixture of medications used to treat symptoms of dyspepsia. The GI cocktail generally contains a mixture of viscous lidocaine, an antacid, and an anticholinergic. The GI cocktail is commonly prescribed in the hospital or emergency department, and has been used to help distinguish chest pain as either gastrointestinal or cardiac. While it has been widely used in the treatment of dyspepsia, studies have suggested that the GI cocktail is only as effective as antacids alone.

<span class="mw-page-title-main">Blood in stool</span> Medical condition of blood in the feces

Blood in stool looks different depending on how early it enters the digestive tract—and thus how much digestive action it has been exposed to—and how much there is. The term can refer either to melena, with a black appearance, typically originating from upper gastrointestinal bleeding; or to hematochezia, with a red color, typically originating from lower gastrointestinal bleeding. Evaluation of the blood found in stool depends on its characteristics, in terms of color, quantity and other features, which can point to its source, however, more serious conditions can present with a mixed picture, or with the form of bleeding that is found in another section of the tract. The term "blood in stool" is usually only used to describe visible blood, and not fecal occult blood, which is found only after physical examination and chemical laboratory testing.

<span class="mw-page-title-main">Gastrinoma</span> Medical condition

Gastrinomas are neuroendocrine tumors (NETs), usually located in the duodenum or pancreas, that secrete gastrin and cause a clinical syndrome known as Zollinger–Ellison syndrome (ZES). A large number of gastrinomas develop in the pancreas or duodenum, with near-equal frequency, and approximately 10% arise as primary neoplasms in lymph nodes of the pancreaticoduodenal region.

Postcholecystectomy syndrome (PCS) describes the presence of abdominal symptoms after a cholecystectomy.

<span class="mw-page-title-main">Chronic intestinal pseudo-obstruction</span> Medical condition

Chronic intestinal pseudo-obstruction (CIPO) is an uncommon syndrome with chronic and recurrent symptoms that suggest intestinal obstruction in the absence of any mechanical blockage of the lumen. The most common symptoms of CIPO include abdominal pain, constipation, nausea, vomiting, dysphagia, and abdominal distention. CIPO can lead to malnutrition.

The Rome process and Rome criteria are an international effort to create scientific data to help in the diagnosis and treatment of functional gastrointestinal disorders, such as irritable bowel syndrome, functional dyspepsia and rumination syndrome. The Rome diagnostic criteria are set forth by Rome Foundation, a not for profit 501(c)(3) organization based in Raleigh, North Carolina, United States.

<span class="mw-page-title-main">Gastroparesis</span> Medical condition

Gastroparesis is a medical disorder of ineffective neuromuscular contractions (peristalsis) of the stomach, resulting in food and liquid remaining in the stomach for a prolonged period of time. Stomach contents thus exit more slowly into the duodenum of the digestive tract, a medical sign called delayed gastric emptying. The opposite of this, where stomach contents exit quickly into the duodenum, is called dumping syndrome.

<span class="mw-page-title-main">Itopride</span> Chemical compound

Itopride (INN; brand name Ganaton) is a prokinetic benzamide derivative. These drugs inhibit dopamine and acetylcholine esterase enzyme and have a gastrokinetic effect. Itopride is indicated for the treatment of functional dyspepsia and other gastrointestinal conditions. It is a combined D2 receptor antagonist and acetylcholinesterase inhibitor. Itopride is the dimethoxy analog of trimethobenzamide.

Fibrosing colonopathy is a disease that arises in people with cystic fibrosis treated with high doses of pancreatic enzyme supplements. Symptoms are non-specific with abdominal pain, abdominal swelling, vomiting, and constipation.

<span class="mw-page-title-main">Inflammatory fibroid polyp</span> Medical condition

An inflammatory fibroid polyp(IFP) is an uncommon digestive system tumor. J. Vanek initially identified it as a separate pathological entity in 1949 when he reported six case reports of eosinophilic infiltration in gastric submucosal granulomas. It is a single, non-encapsulated polypoid lesion that is typically submucosal. It is characterized by a large number of small blood vessels, oedematous connective tissue, and an inflammatory eosinophilic infiltrate.

Abdominal migraine(AM) is a functional disorder that usually manifests in childhood and adolescence, without a clear pathologic mechanism or biochemical irregularity. Children frequently experience sporadic episodes of excruciating central abdominal pain accompanied by migrainous symptoms like nausea, vomiting, severe headaches, and general pallor. Abdominal migraine can be diagnosed based on clinical criteria and the exclusion of other disorders.

<span class="mw-page-title-main">Colonic ulcer</span> Medical condition

Colonic ulcer can occur at any age, in children however they are rare. Most common symptoms are abdominal pain and hematochezia.

<span class="mw-page-title-main">Acid peptic diseases</span> Overview of the acid peptic diseases of the stomach and gastrointestinal tract

Acid peptic diseases, such as peptic ulcers, Zollinger-Ellison syndrome, and gastroesophageal reflux disease, are caused by distinct but overlapping pathogenic mechanisms involving acid effects on mucosal defense. Acid reflux damages the esophageal mucosa and may also cause laryngeal tissue injury, leading to the development of pulmonary symptoms.

References

  1. 1 2 3 4 5 "UpToDate". uptodate.com. Retrieved December 28, 2023.
  2. 1 2 3 4 Francis, Pilin; Zavala, Stacey R. (August 17, 2023). "Functional Dyspepsia". StatPearls Publishing. PMID   32119450 . Retrieved December 28, 2023.
  3. ↑ Geeraerts, Brecht; Tack, Jan (2008). "Functional dyspepsia: past, present, and future". Journal of Gastroenterology. 43 (4): 251–255. doi:10.1007/s00535-008-2167-8. ISSN   0944-1174. PMID   18458839.
  4. 1 2 3 Talley, Nicholas J.; Cook, Dane R. (2019). "Functional Dyspepsia". Essential Medical Disorders of the Stomach and Small Intestine. Cham: Springer International Publishing. pp. 155–172. doi:10.1007/978-3-030-01117-8_8. ISBN   978-3-030-01116-1.
  5. 1 2 3 Tack, Jan; Bisschops, Raf; Sarnelli, Giovanni (2004). "Pathophysiology and treatment of functional dyspepsia". Gastroenterology. 127 (4). Elsevier BV: 1239–1255. doi:10.1053/j.gastro.2004.05.030. ISSN   0016-5085. PMID   15481001.
  6. ↑ Agreus, L (2002-05-01). "Natural history of dyspepsia". Gut. 50 (Supplement 4). BMJ: iv2–iv9. doi:10.1136/gut.50.suppl_4.iv2. ISSN   0017-5749. PMC   1867692 . PMID   11953337.
  7. ↑ Madisch, Ahmed; Andresen, Viola; Enck, Paul; Labenz, Joachim; Frieling, Thomas; Schemann, Michael (2018-03-30). "The Diagnosis and Treatment of Functional Dyspepsia". Deutsches Ärzteblatt International. Deutscher Arzte-Verlag GmbH. doi:10.3238/arztebl.2018.0222. ISSN   1866-0452. PMC   5938438 .
  8. ↑ Tack, Jan; Piessevaux, Hubert; Coulie, Bernard; Caenepeel, Philip; Janssens, Jozef (1998). "Role of impaired gastric accommodation to a meal in functional dyspepsia". Gastroenterology. 115 (6). Elsevier BV: 1346–1352. doi:10.1016/s0016-5085(98)70012-5. ISSN   0016-5085. PMID   9834261.
  9. ↑ Farré, Ricard; Tack, Jan (2013). "Food and Symptom Generation in Functional Gastrointestinal Disorders: Physiological Aspects". American Journal of Gastroenterology. 108 (5). Ovid Technologies (Wolters Kluwer Health): 698–706. doi:10.1038/ajg.2013.24. ISSN   0002-9270. PMID   23458851.
  10. 1 2 Vanheel, H; Carbone, F; Valvekens, L; Simren, M; Tornblom, H; Vanuytsel, T; Van Oudenhove, L; Tack, J (2017). "Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria". American Journal of Gastroenterology. 112 (1). Ovid Technologies (Wolters Kluwer Health): 132–140. doi:10.1038/ajg.2016.499. ISSN   0002-9270.
  11. ↑ Bisschops, R; Karamanolis, G; Arts, J; Caenepeel, P; Verbeke, K; Janssens, J; Tack, J (2008-06-02). "Relationship between symptoms and ingestion of a meal in functional dyspepsia". Gut. 57 (11). BMJ: 1495–1503. doi:10.1136/gut.2007.137125. ISSN   0017-5749. PMID   18519430.
  12. 1 2 3 4 5 6 7 Enck, Paul; Azpiroz, Fernando; Boeckxstaens, Guy; Elsenbruch, Sigrid; Feinle-Bisset, Christine; Holtmann, Gerald; Lackner, Jeffrey M.; Ronkainen, Jukka; Schemann, Michael; Stengel, Andreas; Tack, Jan; Zipfel, Stephan; Talley, Nicholas J. (2017-11-03). "Functional dyspepsia". Nature Reviews Disease Primers. 3 (1). Springer Science and Business Media LLC. doi:10.1038/nrdp.2017.81. ISSN   2056-676X. PMID   29099093.
  13. ↑ Ford, Alexander C; Marwaha, Avantika; Sood, Ruchit; Moayyedi, Paul (2014-08-21). "Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis" (PDF). Gut. 64 (7). BMJ: 1049–1057. doi:10.1136/gutjnl-2014-307843. ISSN   0017-5749. PMID   25147201.
  14. ↑ Ford, A. C; Forman, D.; Bailey, A. G; Axon, A. T R; Moayyedi, P. (2007-03-01). "Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study". Gut. 56 (3). BMJ: 321–327. doi:10.1136/gut.2006.099846. ISSN   0017-5749. PMC   1856829 . PMID   16908511.
  15. 1 2 3 4 5 6 7 8 9 10 11 12 Ford, Alexander C; Mahadeva, Sanjiv; Carbone, M Florencia; Lacy, Brian E; Talley, Nicholas J (2020). "Functional dyspepsia" (PDF). The Lancet. 396 (10263). Elsevier BV: 1689–1702. doi:10.1016/s0140-6736(20)30469-4. ISSN   0140-6736.
  16. ↑ Aro, Pertti; Talley, Nicholas J.; Johansson, Sven-Erik; Agréus, Lars; Ronkainen, Jukka (2015). "Anxiety Is Linked to New-Onset Dyspepsia in the Swedish Population: A 10-Year Follow-up Study". Gastroenterology. 148 (5). Elsevier BV: 928–937. doi:10.1053/j.gastro.2015.01.039. ISSN   0016-5085.
  17. ↑ Koloski, N A; Jones, M; Kalantar, J; Weltman, M; Zaguirre, J; Talley, N J (2012-01-10). "The brain–gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study". Gut. 61 (9). BMJ: 1284–1290. doi:10.1136/gutjnl-2011-300474. ISSN   0017-5749. PMID   22234979.
  18. ↑ Koloski, N. A.; Jones, M.; Talley, N. J. (2016-07-22). "Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study". Alimentary Pharmacology & Therapeutics. 44 (6). Wiley: 592–600. doi:10.1111/apt.13738. ISSN   0269-2813. PMID   27444264.
  19. ↑ Futagami, S.; Itoh, T.; Sakamoto, C. (2014-10-27). "Systematic review with meta-analysis: post-infectious functional dyspepsia". Alimentary Pharmacology & Therapeutics. 41 (2). Wiley: 177–188. doi:10.1111/apt.13006. ISSN   0269-2813. PMID   25348873.
  20. 1 2 Oustamanolakis, Pantelis; Tack, Jan (2012). "Dyspepsia". Journal of Clinical Gastroenterology. 46 (3). Ovid Technologies (Wolters Kluwer Health): 175–190. doi:10.1097/mcg.0b013e318241b335. ISSN   0192-0790.
  21. ↑ Maes, Bart D.; Ghoos, Yvo F.; Hiele, Martin I.; Rutgeerts, Paul J. (1997). "Gastric emptying rate of solids in patients with nonulcer dyspepsia". Digestive Diseases and Sciences. 42 (6). Springer Science and Business Media LLC: 1158–1162. doi:10.1023/a:1018881419010. ISSN   0163-2116. PMID   9201077.
  22. ↑ Sarnelli, Giovanni; Caenepeel, Philip; Geypens, Benny; Janssens, Jozef; Tack, Jan (2003). "Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia". The American Journal of Gastroenterology. 98 (4). Ovid Technologies (Wolters Kluwer Health): 783–788. doi:10.1111/j.1572-0241.2003.07389.x. ISSN   0002-9270. PMID   12738456.
  23. ↑ Quarter, A. O.; De Wit, N. J.; Lodder, A. C.; Numans, M. E.; Smout, A. J. P. M.; Hoes, A. W. (1998). "Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis". Digestive Diseases and Sciences. 43 (9). Springer Science and Business Media LLC: 2028–2033. doi:10.1023/a:1018803129779. ISSN   0163-2116. PMID   9753269.
  24. ↑ Troncon, L E; Thompson, D G; Ahluwalia, N K; Barlow, J; Heggie, L (1995-07-01). "Relations between upper abdominal symptoms and gastric distension abnormalities in dysmotility like functional dyspepsia and after vagotomy". Gut. 37 (1). BMJ: 17–22. doi:10.1136/gut.37.1.17. ISSN   0017-5749. PMC   1382761 . PMID   7672673.
  25. ↑ Gilja, O. H.; Hausken, T.; Wilhelmsen, I.; Berstad, A. (1996). "Impaired accommodation of proximal stomach to a meal in functional dyspepsia". Digestive Diseases and Sciences. 41 (4). Springer Science and Business Media LLC: 689–696. doi:10.1007/bf02213124. ISSN   0163-2116. PMID   8674389.
  26. ↑ Bortolotti, M.; Bolondi, L.; Santi, V.; Sarti, P.; Brunelli, F.; Barbara, L. (1995). "Patterns of Gastric Emptying in Dysmotility-Like Dyspepsia". Scandinavian Journal of Gastroenterology. 30 (5). Informa UK Limited: 408–410. doi:10.3109/00365529509093299. ISSN   0036-5521. PMID   7638564.
  27. ↑ Coffin, Benoit; Azpiroz, Fernando; Guarner, Francisco; Malagelada, Juan-R. (1994). "Selective gastric hypersensitivity and reflex hyporeactivity in functional dyspepsia". Gastroenterology. 107 (5). Elsevier BV: 1345–1351. doi:10.1016/0016-5085(94)90536-3. ISSN   0016-5085. PMID   7926499.
  28. ↑ Mertz, H; Fullerton, S; Naliboff, B; Mayer, E A (1998-06-01). "Symptoms and visceral perception in severe functional and organic dyspepsia". Gut. 42 (6). BMJ: 814–822. doi:10.1136/gut.42.6.814. ISSN   0017-5749. PMC   1727129 . PMID   9691920.
  29. 1 2 Greydanus, Martin P.; Vassallo, Mario; Camilleri, Michael; Nelson, Daniel K.; Hanson, Russell B.; Thomforde, George M. (1991). "Neurohormonal Factors in Functional Dyspepsia: Insights on Pathophysiological Mechanisms". Gastroenterology. 100 (5): 1311–1318. doi:10.1016/0016-5085(91)70018-S.
  30. ↑ Holtmann, G; Goebell, H; Talley, J (March 1996). "Impaired small intestinal peristaltic reflexes and sensory thresholds are independent functional disturbances in patients with chronic unexplained dyspepsia". The American Journal of Gastroenterology. 91 (3): 485–491. PMID   8633496.
  31. ↑ Bouin, M.; Lupien, F.; Riberdy, M.; Boivin, M.; Plourde, V.; Poitras, P. (2004-04-08). "Intolerance to visceral distension in functional dyspepsia or irritable bowel syndrome: an organ specific defect or a pan intestinal dysregulation?". Neurogastroenterology & Motility. 16 (3). Wiley: 311–314. doi:10.1111/j.1365-2982.2004.00511.x. ISSN   1350-1925. PMID   15198653.
  32. ↑ Zhong, Laurie; Shanahan, Erin R; Raj, Ashok; Koloski, Natasha A; Fletcher, Linda; Morrison, Mark; Walker, Marjorie M; Talley, Nicholas J; Holtmann, Gerald (2016-08-03). "Dyspepsia and the microbiome: time to focus on the small intestine". Gut. 66 (6). BMJ: 1168–1169. doi:10.1136/gutjnl-2016-312574. ISSN   0017-5749. PMID   27489239.
  33. 1 2 Pavlidis, P.; Powell, N.; Vincent, R. P.; Ehrlich, D.; Bjarnason, I.; Hayee, B. (2015-07-29). "Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?". Alimentary Pharmacology & Therapeutics. 42 (7). Wiley: 802–817. doi:10.1111/apt.13333. ISSN   0269-2813.
  34. ↑ Kakiyama, Genta; Pandak, William M.; Gillevet, Patrick M.; Hylemon, Phillip B.; Heuman, Douglas M.; Daita, Kalyani; Takei, Hajime; Muto, Akina; Nittono, Hiroshi; Ridlon, Jason M.; White, Melanie B.; Noble, Nicole A.; Monteith, Pamela; Fuchs, Michael; Thacker, Leroy R.; Sikaroodi, Masoumeh; Bajaj, Jasmohan S. (2013). "Modulation of the fecal bile acid profile by gut microbiota in cirrhosis". Journal of Hepatology. 58 (5). Elsevier BV: 949–955. doi:10.1016/j.jhep.2013.01.003. ISSN   0168-8278. PMC   3936319 . PMID   23333527.
  35. ↑ Beeckmans, Dorien; Riethorst, Danny; Augustijns, Patrick; Vanuytsel, Tim; Farré, Ricard; Tack, Jan; Vanheel, Hanne (2018). "Altered duodenal bile salt concentration and receptor expression in functional dyspepsia". United European Gastroenterology Journal. 6 (9). Wiley: 1347–1355. doi:10.1177/2050640618799120. ISSN   2050-6406. PMC   6206534 .
  36. ↑ Ford, Alexander C.; Talley, Nicholas J. (2011-02-18). "Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review". Journal of Gastroenterology. 46 (4). Springer Science and Business Media LLC: 421–431. doi:10.1007/s00535-011-0379-9. ISSN   0944-1174. PMID   21331765.
  37. ↑ Vanheel, Hanne; Vicario, Maria; Vanuytsel, Tim; Van Oudenhove, Lukas; Martinez, Cristina; Keita, Åsa V; Pardon, Nicolas; Santos, Javier; Söderholm, Johan D; Tack, Jan; Farré, Ricard (2013-03-08). "Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia". Gut. 63 (2). BMJ: 262–271. doi:10.1136/gutjnl-2012-303857. ISSN   0017-5749. PMID   23474421.
  38. ↑ Gargala, Gilles (2007). "Duodenal intraepithelial T lymphocytes in patients with functional dyspepsia". World Journal of Gastroenterology. 13 (16). Baishideng Publishing Group Inc.: 2333–2338. doi: 10.3748/wjg.v13.i16.2333 . ISSN   1007-9327. PMC   4147143 . PMID   17511033.
  39. ↑ Talley, Nicholas J.; Walker, Marjorie M.; Aro, Pertti; Ronkainen, Jukka; Storskrubb, Tom; Hindley, Laura A.; Harmsen, W. Scott; Zinsmeister, Alan R.; Agréus, Lars (2007). "Non-ulcer Dyspepsia and Duodenal Eosinophilia: An Adult Endoscopic Population-Based Case-Control Study". Clinical Gastroenterology and Hepatology. 5 (10). Elsevier BV: 1175–1183. doi:10.1016/j.cgh.2007.05.015. ISSN   1542-3565.
  40. ↑ Ronkainen, Jukka; Aro, Pertti; Walker, Marjorie M.; Agréus, Lars; Johansson, Sven-Erik; Jones, Mike; Talley, Nicholas J. (2019-05-20). "Duodenal eosinophilia is associated with functional dyspepsia and new onset gastro-oesophageal reflux disease". Alimentary Pharmacology & Therapeutics. 50 (1). Wiley: 24–32. doi:10.1111/apt.15308. ISSN   0269-2813. PMID   31107579.
  41. ↑ Rodiño-Janeiro, Bruno K; Alonso-Cotoner, Carmen; Pigrau, Marc; Lobo, Beatriz; Vicario, María; Santos, Javier (2015-01-01). "Role of Corticotropin-releasing Factor in Gastrointestinal Permeability". Journal of Neurogastroenterology and Motility. 21 (1). The Korean Society of Neurogastroenterology and Motility: 033–050. doi:10.5056/jnm14084. ISSN   2093-0879. PMID   25537677.
  42. ↑ Vanuytsel, Tim; Vanormelingen, Christophe; Vanheel, Hanne; Masaoka, Tatsuhiro; Salim Rasoel, Shadea; Tóth, Joran; Houben, Els; Verbeke, Kristin; De Hertogh, Gert; Berghe, Pieter Vanden; Tack, Jan; Farré, Ricard (2014-10-29). "From Intestinal Permeability to Dysmotility: The Biobreeding Rat as a Model for Functional Gastrointestinal Disorders". PLOS ONE. 9 (10). Public Library of Science (PLoS): e111132. doi: 10.1371/journal.pone.0111132 . ISSN   1932-6203. PMC   4212994 . PMID   25354336.
  43. ↑ Vanuytsel, Tim; van Wanrooy, Sander; Vanheel, Hanne; Vanormelingen, Christophe; Verschueren, Sofie; Houben, Els; Salim Rasoel, Shadea; Tόth, Joran; Holvoet, Lieselot; Farré, Ricard; Van Oudenhove, Lukas; Boeckxstaens, Guy; Verbeke, Kristin; Tack, Jan (2013-10-23). "Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism". Gut. 63 (8). BMJ: 1293–1299. doi:10.1136/gutjnl-2013-305690. ISSN   0017-5749. PMID   24153250.
  44. ↑ Liu, P.; Fan, Y.; Wei, Y.; Zeng, F.; Li, R.; Fei, N.; Qin, W. (2018-04-23). "Altered structural and functional connectivity of the insula in functional dyspepsia". Neurogastroenterology & Motility. 30 (9). Wiley. doi:10.1111/nmo.13345. ISSN   1350-1925. PMID   29687532.
  45. ↑ Chen, Yanwen; Wang, Ruifeng; Hou, Bo; Feng, Feng; Fang, Xiucai; Zhu, Liming; Sun, Xiaohong; Wang, Zhifeng; Ke, Meiyun (2018-04-30). "Regional Brain Activity During Rest and Gastric Water Load in Subtypes of Functional Dyspepsia: A Preliminary Brain Functional Magnetic Resonance Imaging Study". Journal of Neurogastroenterology and Motility. 24 (2). The Korean Society of Neurogastroenterology and Motility: 268–279. doi:10.5056/jnm17076. ISSN   2093-0879. PMID   29605982.
  46. ↑ Lin, Zhiyue; Eaker, Ervin Y; Sarosiek, Irene; McCallum, Richard W (1999). "Gastric Myoelectrical Activity and Gastric Emptying in Patients With Functional Dyspepsia". American Journal of Gastroenterology. 94 (9). Ovid Technologies (Wolters Kluwer Health): 2384–2389. doi:10.1111/j.1572-0241.1999.01362.x. ISSN   0002-9270.
  47. ↑ Parkman, Henry P.; Miller, Mark A.; Trate, Douglas; Knight, Linda C.; Urbain, Jean-Luc; Maurer, Alan H.; Fisher, Robert S. (1997). "Electrogastrography and Gastric Emptying Scintigraphy Are Complementary for Assessment of Dyspepsia". Journal of Clinical Gastroenterology. 24 (4). Ovid Technologies (Wolters Kluwer Health): 214–219. doi:10.1097/00004836-199706000-00006. ISSN   0192-0790. PMID   9252843.
  48. ↑ Holtmann, G; Goebell, H; Jockenhoevel, F; Talley, N J (1998-04-01). "Altered vagal and intestinal mechanosensory function in chronic unexplained dyspepsia". Gut. 42 (4). BMJ: 501–506. doi:10.1136/gut.42.4.501. ISSN   0017-5749. PMC   1727067 .
  49. ↑ Hausken, T; Svebak, S; Wilhelmsen, I; Haug, T T; Olafsen, K; Pettersson, E; Hveem, K; Berstad, A (1993). "Low vagal tone and antral dysmotility in patients with functional dyspepsia". Psychosomatic Medicine. 55 (1). Ovid Technologies (Wolters Kluwer Health): 12–22. doi:10.1097/00006842-199301000-00004. ISSN   0033-3174. PMID   8446737.
  50. ↑ Troncon, L E; Thompson, D G; Ahluwalia, N K; Barlow, J; Heggie, L (1995-07-01). "Relations between upper abdominal symptoms and gastric distension abnormalities in dysmotility like functional dyspepsia and after vagotomy". Gut. 37 (1). BMJ: 17–22. doi:10.1136/gut.37.1.17. ISSN   0017-5749. PMC   1382761 . PMID   7672673.
  51. ↑ Haug, T T; Svebak, S; Hausken, T; Wilhelmsen, I; Berstad, A; Ursin, H (1994). "Low vagal activity as mediating mechanism for the relationship between personality factors and gastric symptoms in functional dyspepsia". Psychosomatic Medicine. 56 (3). Ovid Technologies (Wolters Kluwer Health): 181–186. doi:10.1097/00006842-199405000-00001. ISSN   0033-3174. PMID   8084961.
  52. ↑ Bennett, E. J.; Kellow, J. E.; Cowan, H.; Scott, A. M.; Shuter, B.; Langeluddecke, P. M.; Hoschl, R.; Jones, M. P.; Tennant, C. C. (1992). "Suppression of Anger and Gastric Emptying in Patients with Functional Dyspepsia". Scandinavian Journal of Gastroenterology. 27 (10). Informa UK Limited: 869–874. doi:10.3109/00365529209000156. ISSN   0036-5521.
  53. 1 2 3 Stanghellini, Vincenzo; Chan, Francis K.L.; Hasler, William L.; Malagelada, Juan R.; Suzuki, Hidekazu; Tack, Jan; Talley, Nicholas J. (2016). "Gastroduodenal Disorders". Gastroenterology. 150 (6). Elsevier BV: 1380–1392. doi:10.1053/j.gastro.2016.02.011. ISSN   0016-5085.
  54. 1 2 3 4 5 6 7 8 "Rome IV Criteria". Rome Foundation. 2023-03-06. Retrieved 2024-04-12.
  55. ↑ Moayyedi, Paul; Talley, Nicholas J.; Fennerty, M. Brian; Vakil, Nimish (2006-04-05). "Can the Clinical History Distinguish Between Organic and Functional Dyspepsia?". JAMA. 295 (13). American Medical Association (AMA): 1566. doi:10.1001/jama.295.13.1566. ISSN   0098-7484. PMID   16595759.
  56. 1 2 Moayyedi, Paul M; Lacy, Brian E; Andrews, Christopher N; Enns, Robert A; Howden, Colin W; Vakil, Nimish (2017). "ACG and CAG Clinical Guideline: Management of Dyspepsia". American Journal of Gastroenterology. 112 (7). Ovid Technologies (Wolters Kluwer Health): 988–1013. doi:10.1038/ajg.2017.154. ISSN   0002-9270. PMID   28631728.
  57. ↑ FORD, A. C.; CHING, E.; MOAYYEDI, P. (2009-06-15). "Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia". Alimentary Pharmacology & Therapeutics. 30 (1). Wiley: 28–36. doi:10.1111/j.1365-2036.2009.04008.x. ISSN   0269-2813. PMID   19416130.
  58. ↑ Ford, Alexander C.; Marwaha, Avantika; Lim, Allen; Moayyedi, Paul (2010). "What Is the Prevalence of Clinically Significant Endoscopic Findings in Subjects With Dyspepsia? Systematic Review and Meta-analysis". Clinical Gastroenterology and Hepatology. 8 (10). Elsevier BV: 830–837.e2. doi:10.1016/j.cgh.2010.05.031. ISSN   1542-3565. PMID   20541625.
  59. ↑ Chey, William D; Leontiadis, Grigorios I; Howden, Colin W; Moss, Steven F (2017). "ACG Clinical Guideline: Treatment of Helicobacter pylori Infection". American Journal of Gastroenterology. 112 (2). Ovid Technologies (Wolters Kluwer Health): 212–239. doi:10.1038/ajg.2016.563. ISSN   0002-9270.
  60. ↑ Moayyedi, P. (2000-09-16). "Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia". BMJ. 321 (7262): 659–664. doi:10.1136/bmj.321.7262.659. ISSN   0959-8138. PMC   27478 . PMID   10987767.
  61. ↑ Heikkinen, Markku; Räsänen, Heikki; Färkkilä, Martti (2005). "Clinical value of ultrasound in the evaluation of dyspepsia in primary health care". Scandinavian Journal of Gastroenterology. 40 (8). Informa UK Limited: 980–984. doi:10.1080/00365520510015845. ISSN   0036-5521. PMID   16165712.
  62. ↑ Van den Houte, Karen; Carbone, Florencia; Goelen, Nick; Schol, Jolien; Masuy, Imke; Arts, Joris; Caenepeel, Philip; Staessen, Dirk; Vergauwe, Philippe; Van Roey, Guy; Latour, Pascale; Piessevaux, Hubert; Maldague, Philippe; Gerkens, Ariane; Wuestenberghs, Fabien; Vandenberghe, Alain; Tack, Jan (2021). "Effects of Rome IV Definitions of Functional Dyspepsia Subgroups in Secondary Care". Clinical Gastroenterology and Hepatology. 19 (8). Elsevier BV: 1620–1626. doi:10.1016/j.cgh.2020.06.043. ISSN   1542-3565.
  63. ↑ Sugano, Kentaro; Tack, Jan; Kuipers, Ernst J; Graham, David Y; El-Omar, Emad M; Miura, Soichiro; Haruma, Ken; Asaka, Masahiro; Uemura, Naomi; Malfertheiner, Peter (2015-07-17). "Kyoto global consensus report on Helicobacter pylori gastritis". Gut. 64 (9). BMJ: 1353–1367. doi:10.1136/gutjnl-2015-309252. hdl: 1765/88609 . ISSN   0017-5749. PMID   26187502.
  64. ↑ Du, Li-Jun; Chen, Bin-Rui; Kim, John J; Kim, Sarah; Shen, Jin-Hua; Dai, Ning (2016-03-28). "Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis". World Journal of Gastroenterology. 22 (12). Baishideng Publishing Group Inc.: 3486–3495. doi: 10.3748/wjg.v22.i12.3486 . ISSN   1007-9327. PMC   4806206 . PMID   27022230.
  65. ↑ Barbera, Roberta; Feinle, Christine; Read, Nicholas W. (1995). "Nutrient-specific modulation of gastric mechanosensitivity in patients with functional dyspepsia". Digestive Diseases and Sciences. 40 (8). Springer Science and Business Media LLC: 1636–1641. doi:10.1007/bf02212683. ISSN   0163-2116. PMID   7648962.
  66. ↑ Barbera, Roberta; Feinle, Christine; Read, Nicholas W. (1995). "Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia". European Journal of Gastroenterology & Hepatology. 7 (11). Ovid Technologies (Wolters Kluwer Health): 1051–1057. doi:10.1097/00042737-199511000-00007. ISSN   0954-691X. PMID   8680904.
  67. ↑ Boekema, Paul J.; Samsom, Melvin; Roelofs, Jan M.M.; Smout, André J.P.M. (2001). "Effect of coffee on motor and sensory function of proximal stomach". Digestive Diseases and Sciences. 46 (5). Springer Science and Business Media LLC: 945–951. doi:10.1023/a:1010733222245. ISSN   0163-2116. PMID   11341663.
  68. ↑ Bortolotti, M.; Coccia, G.; Grossi, G.; Miglioli, M. (2002-05-27). "The treatment of functional dyspepsia with red pepper". Alimentary Pharmacology & Therapeutics. 16 (6). Wiley: 1075–1082. doi:10.1046/j.1365-2036.2002.01280.x. ISSN   0269-2813. PMID   12030948.
  69. 1 2 TACK, J (2008). "Prokinetics and fundic relaxants in upper functional GI disorders". Current Opinion in Pharmacology. 8 (6). Elsevier BV: 690–696. doi:10.1016/j.coph.2008.09.009. ISSN   1471-4892. PMID   18940266.
  70. ↑ Tack, Jan; Janssen, Pieter; Masaoka, Tatsuhiro; Farré, Ricard; Van Oudenhove, Lukas (2012). "Efficacy of Buspirone, a Fundus-Relaxing Drug, in Patients With Functional Dyspepsia". Clinical Gastroenterology and Hepatology. 10 (11). Elsevier BV: 1239–1245. doi:10.1016/j.cgh.2012.06.036. ISSN   1542-3565. PMID   22813445.
  71. ↑ Miwa, Hiroto; Nagahara, A; Tominaga, K; Yokoyama, T; Sawada, Y; Inoue, K; Ashida, Kiyoshi; Fukuchi, T; Hojo, M; Yamashita, H; Tomita, T; Hori, K; Oshima, T (2009-07-28). "Efficacy of the 5-HT1A Agonist Tandospirone Citrate in Improving Symptoms of Patients With Functional Dyspepsia: A Randomized Controlled Trial". The American Journal of Gastroenterology. 104 (11). Ovid Technologies (Wolters Kluwer Health): 2779–2787. doi:10.1038/ajg.2009.427. ISSN   0002-9270. PMID   19638966.
  72. ↑ Matsueda, Kei; Hongo, Michio; Tack, Jan; Saito, Youichi; Kato, Hiroki (2011-12-09). "A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia". Gut. 61 (6). BMJ: 821–828. doi:10.1136/gutjnl-2011-301454. ISSN   0017-5749. PMC   3345932 .
  73. ↑ Tack, Jan; Ly, Huynh Giao; Carbone, Florencia; Vanheel, Hanne; Vanuytsel, Tim; Holvoet, Lieselot; Boeckxstaens, Guy; Caenepeel, Philip; Arts, Joris; Van Oudenhove, Lukas (2016). "Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss". Clinical Gastroenterology and Hepatology. 14 (3). Elsevier BV: 385–392.e4. doi:10.1016/j.cgh.2015.09.043. ISSN   1542-3565. PMID   26538208.
  74. ↑ Moayyedi, Paul; Delaney, Brendan C.; Vakil, Nimish; Forman, David; Talley, Nicholas J. (2004). "The efficacy of proton pump inhibitors in nonulcer dyspepsia: A systematic review and economic analysis". Gastroenterology. 127 (5). Elsevier BV: 1329–1337. doi:10.1053/j.gastro.2004.08.026. ISSN   0016-5085. PMID   15521002.
  75. ↑ Suzuki, Hidekazu; Kusunoki, Hiroaki; Kamiya, Takeshi; Futagami, Seiji; Yamaguchi, Yasuharu; Nishizawa, Toshihiro; Iwasaki, Eisuke; Matsuzaki, Juntaro; Takahashi, Shinichi; Sakamoto, Choitsu; Haruma, Ken; Joh, Takashi; Asakura, Keiko; Hibi, Toshifumi (2013). "Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial". United European Gastroenterology Journal. 1 (6). Wiley: 445–452. doi:10.1177/2050640613510904. ISSN   2050-6406. PMC   4040742 . PMID   24917996.
  76. ↑ Talley, Nicholas J.; Ford, Alexander C. (2015-11-05). "Functional Dyspepsia" (PDF). New England Journal of Medicine. 373 (19): 1853–1863. doi:10.1056/NEJMra1501505. ISSN   0028-4793.
  77. ↑ Olafsdottir, Linda Bjork; Gudjonsson, Hallgrimur; Jonsdottir, Heidur Hrund; Bjornsson, Einar; Thjodleifsson, Bjarni (2012). "Natural history of functional gastrointestinal disorders: Comparison of two longitudinal population-based studies". Digestive and Liver Disease. 44 (3). Elsevier BV: 211–217. doi:10.1016/j.dld.2011.10.009. ISSN   1590-8658. PMID   22137573.
  78. ↑ Ford, Alexander C; Forman, David; Bailey, Alastair G; Axon, Anthony T R; Moayyedi, Paul (2012). "Effect of Dyspepsia on Survival: A Longitudinal 10-Year Follow-Up Study". American Journal of Gastroenterology. 107 (6). Ovid Technologies (Wolters Kluwer Health): 912–921. doi:10.1038/ajg.2012.69. ISSN   0002-9270.
  79. ↑ Mahadeva, S.; Ford, A. C. (2015-08-30). "Clinical and epidemiological differences in functional dyspepsia between the East and the West". Neurogastroenterology & Motility. 28 (2). Wiley: 167–174. doi:10.1111/nmo.12657. ISSN   1350-1925.
  80. ↑ Napthali, Kate; Koloski, Natasha; Walker, Marjorie M; Talley, Nicholas J (2016). "Women and Functional Dyspepsia". Women's Health. 12 (2). SAGE Publications: 241–250. doi:10.2217/whe.15.88. hdl: 1959.13/1347766 . ISSN   1745-5065.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.